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Abstract The human a2-plasmin inhibitor (A2PI) pos-
sesses unique N- and C-terminal extensions that significantly
influence its biological activities. The C-terminal segment,
A2PIC (Asn398-Lys452), contains six lysines thought to be
involved in the binding to lysine-binding sites in the kringle
domains of human plasminogen, of which four (Lys422,
Lys429, Lys436, Lys452) are completely and two (Lys406,
Lys415) are partially conserved. Multiple Lys to Ala mutants
of A2PIC were expressed in Escherichia coli and used in
intrinsic fluorescence titrations with kringle domains K1,
K4, K4 ? 5, and K1 ? 2 ? 3 of human plasminogen. We
were able to identify the C-terminal Lys452 as the main
binding partner in recombinant A2PIC (rA2PIC) constructs
with isolated kringles. We could show a cooperative, zipper-
like enhancement of the interaction between C-terminal
Lys452 and internal Lys436 of rA2PIC and isolated
K1 ? 2 ? 3, whereas the other internal lysine residues
contribute only to a minor extent to the binding process.
Sulfated Tyr445 in the unique C-terminal segment revealed
no influence on the binding affinity to kringle domains.
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Abbreviations
6-AHA 6-Aminohexanoic acid
A2PI Human a2-plasmin inhibitor
A2PIC C-terminal moiety of A2PI (Asn398-Lys452)
rA2PIC Recombinant A2PIC (A2PIC/Pro399Ala)
FXa Activated coagulation factor X
His-tag Peptide MNHKVH6MELGTIEGR
K1 Kringle 1 of Pgn (Cys84-Cys162), generated as
rK1 (Lys78-Glu164)
K2 Kringle 2 of Pgn (Cys166-Cys243), generated
as rK2 (Cys162Thr/Glu163Ser/Glu164-Thr244/
Cys169Gly)
K3 Kringle 3 of Pgn (Cys256-Cys333), generated
as rK3 (Thr253-Ser335/Cys297Ser)
rK3mut Mutated K3 domain of Pgn (rK3/Lys311Asp)
K4 Kringle 4 of Pgn (Cys358-Cys435), generated
as fragment Val355-Ala440 of Pgn
K5 Kringle 5 of Pgn (Cys462-Cys541), generated
as rK5 (Thr456-Ala543, Pro457Ala)
K1–3 Kringles 1–3 of Pgn (Cys84-Cys333),
generated as fragment Tyr80-Val338 of Pgn
K4–5 Kringles 4–5 of Pgn (Cys358-Cys541),
generated as rK4–5 (Val355-Phe546)
LB Broth Luria–Bertani Broth
LBS Lysine-binding site
PAN Plasminogen N-terminal domain
Pgn Human plasminogen
Plm Human plasmin
RCL Reactive center loop
Serpin Serine protease inhibitor
t-AMCHA trans-4-(Aminomethyl)
cyclohexanecarboxylic acid
Introduction
The human a2-plasmin inhibitor (A2PI), a member of the
serine protease inhibitor (serpin) super family [1], was
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discovered in 1976 [2–4]. A2PI is a single-chain plasma
glycoprotein [3, 5] synthesized in the liver [6, 7] with a
carbohydrate content of 14% [5]. It has been shown that
A2PI contains four fully glycosylated N-glycosylation sites
(Asn87, Asn250, Asn270, and Asn277) [8, 9]. Two different
N-terminal forms of A2PI circulate in human plasma:
Met-A2PI, a 464-residue protein with Met as N-terminus,
and Asn-A2PI, a 452-residue form with Asn as N-terminus
[10, 11]. The numbering in this publication is according to
Asn-A2PI. Mature human A2PI, which corresponds to
Asn-A2PI [10–13], contains four cysteine residues (Cys31,
Cys64, Cys104, and Cys113), two of which form a single
disulfide bridge (Cys31-Cys104) [14] and a sulfated tyrosine
residue (Tyr445) of unknown function [15]. A2PI possesses
unique N- and C-terminal extensions that significantly
influence its biological activities. The N-terminal portion at
Gln2 is cross-linked to Lys303 in the Aa chain of fibrin
(ogen) by activated coagulation factor XIIIa [16, 17]. The
C-terminal moiety of A2PI (A2PIC) extends approximately
55 amino acids beyond the consensus serpin sequence [12]
and is highly conserved among species, which indicates a
distinct and specific function for the C-terminal Asn398-
Lys452 segment [18] (Scheme 1). It has been shown that
A2PIC mediates the binding to plasmin(ogen) kringles
[19–21]. The X-ray crystal structure of N-terminally trun-
cated murine A2PI, which shares 71% sequence identity
with human A2PI, shows that A2PI exhibits the typical
serpin fold [22]. Unfortunately, the structure of the unique
N- and C-terminal extensions still remains unsolved.
A2PI is the principal physiological inhibitor of plasmin
(Plm) [2–4], the key enzyme of the fibrinolytic cascade.
Plasminogen (Pgn), the zymogen of Plm, is a 90-kDa
multidomain plasma glycoprotein synthesized in the liver
[23]. It is composed of an N-terminal PAN module [24],
five kringle domains [25], and a trypsin-like serine protease
unit [26]. All kringle domains contain a lysine-binding site
(LBS), which is responsible for the interaction of Pgn with,
e.g., fibrin, A2PI, and small molecules with positively
charged group(s) such as lysine and lysine analogous, like
6-aminohexanoic acid (6-AHA) or trans-4-(aminomethyl)
cyclohexanecarboxylic acid (t-AMCHA) (reviewed in
[27]). Plm reacts with A2PI to form an enzymatically
inactive 1:1 equimolar complex [3, 5, 28, 29] upon
cleavage of the scissile peptide bond (Arg365-Met366) in the
reactive center loop (RCL) of A2PI [30]. Kinetic data
suggest a two-step reaction for the rapid inhibition of
Plm: a fast reversible second-order reaction (k1, 3.8 9
107 M-1 s-1) followed by a slower irreversible first-order
transition (k2, 4.2 9 10
7 M-3 s-1) [19, 28, 29, 31, 32]. In
the second step, the scissile peptide bond in the RCL of
A2PI is cleaved by the protease subunit of Plm. The first
step is rate limiting and results in the formation of a non-
covalent complex between A2PIC and kringle domains of
Plm. The complex formation between Plm and A2PI is
competitively inhibited by plasminogen kringles 1–3
(K1–3) and kringle 4 (K4) or by 6-AHA [19]. A2PI inhibits
miniplasmin, a Plm fragment possessing only kringle 5
(K5) and the fully active protease domain, approximately
60-fold slower than intact Plm [31]. 30% of mature A2PI in
human plasma is partially degraded lacking at least 26
residues (Gly427-Lys452) of the C-terminal segment [20].
This truncated form also inhibits Plm less rapidly than
native A2PI [33, 34]. These observations emphasize the
physiological relevance of this non-covalent interaction
between the unique A2PIC and Plm kringle domains.
Human A2PIC contains six lysine residues, of which
four (Lys452, Lys436, Lys429, and Lys422) are completely
and two (Lys406 and Lys415) are partially conserved
(Scheme 1). It is well known that internal as well as
C-terminal lysine residues often exhibit a distinct affinity
for LBS in kringles. Initial studies gave evidence for the
participation of the C-terminal Lys452 residue in the bind-
ing to the Plm kringle domains [18]. Furthermore, a
synthetic C-terminal peptide of A2PI (Gly427-Lys452) has
been shown to competitively block the reversible associa-
tion of A2PI to Plm kringle domains [20, 21]. Substitution
of Lys452 with arginine or its removal with carboxypepti-
dase B was found to reduce the interaction between these
peptides and Plm [21, 35]. These data led to the suggestion
that the multiple lysine residues within A2PIC contribute,
probably in a zipper-like manner, to the binding to the
‘five-kringle array’ in Plm [18, 35]. In contrast to these
Scheme 1 Multiple sequence alignment of human, bovine, murine,
rabbit, and rat A2PIC. The numbering is according to the Asn form of
human A2PI. The Pro399Ala mutation is shaded in gray, sulfated
Tyr445 is underlined, Lys residues are in bold type and the symbols
asterisk, colon, dot, and blank space stand for identity, high, average,
and poor similarity, respectively
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findings, kinetic data by Wang et al. [36, 37] indicate that
Lys436 might play an important role in the interaction
between Plm and A2PI.
To elucidate the exact role of the four completely con-
served lysine residues (Lys452, Lys436, Lys429, and Lys422)
and the partially conserved Lys415 and Lys406 in the binding
to the LBS of Pgn kringle domains, we have expressed wild-
type, single, double, triple, quadruple, quintuple, and sex-
tuple Lys mutants of recombinant A2PIC(Pro399Ala)
(rA2PIC) in Escherichia coli. Association constant (Ka)
values of the different mutant rA2PIC constructs to human
recombinant kringle 1 (rK1) and kringles 4–5 (rK4–5) and
human K4 and K1–3, which were obtained by limited
proteolysis of Pgn with porcine elastase, have been deter-
mined applying intrinsic fluorescence ligand titrations. To
investigate the influence of sulfated Tyr445 in the interaction
with human kringles rK3 and K4, the Ka values of synthetic
peptides Glu442-Lys452 of the C-terminal region of A2PI,
A2PIC(Glu442-Lys452), with and without sulfated Tyr445
have also been obtained by intrinsic fluorescence ligand
titrations.
Materials and methods
Materials
Restriction endonucleases, Pfu DNA Polymerase, T4 DNA
Ligase, activated coagulation factor X (FXa) and trypsin
(porcine, seq. grade modified) came from Promega
(Madison, WI, USA). Porcine elastase was purchased from
Serva (Heidelberg, Germany). UltraPureTM Agarose was
obtained from Invitrogen (Carlsbad, CA, USA). E.Z.N.A.
MicroSpin Gel Extraction Kit was purchased from peQLab
(Erlangen, Germany). GenEluteTM HP Plasmid Miniprep
Kit and Luria–Bertani Broth (LB Broth) were obtained
from Sigma-Aldrich (St. Louis, MO, USA). Primers were
synthesized either by Microsynth (Balgach, Switzerland)
or Sigma-Aldrich. Sephadex G-50m and G-50sf were
purchased from GE Healthcare (Waukesha, WI, USA).
Acrylamide, Bio-Gel P-6DG and Bio-Gel P-300 were from
Bio-Rad (Hercules, CA, USA). Lysine Bio-Gel P-300 was
prepared according to Brunisholz et al. [38] and Ni2?-NTA
Agarose was purchased from QIAGEN (Venlo, The
Netherlands).
Bacterial strains and plasmids
Escherichia coli strain XL1-Blue {recA1 endA1 gyrA96
thi-1 hsdR17 supE44 relA1 lac [F0 proAB lacIqZDM15
Tn10 (Tetr)]} was obtained from Stratagene (La Jolla, CA,
USA) and used for routine transformations and plasmid
preparations. RosettaTM [F– ompT hsdSB(rB
– mB
–) gal dcm
(DE3) pRARE [39] (CamR)] E. coli strain was purchased
from Novagen (Madison, WI, USA) and used for the
expression of recombinant A2PIC (rA2PIC) and rA2PIC
mutants. The pColdII plasmid was obtained from Takara
(Kyoto, Japan) and used for the expression of rA2PIC. The
plasmid contains a lac operator, a cspA 50-untranslated
region, a translation enhancing element, a hexaHis Tag
sequence (His-tag), a multiple cloning site, and a cspA
30-untranslated region immediately upstream of the cspA
transcription initiation site and carries an ampicillin resis-
tance [40]. The pET100/D-TOPO plasmid (Invitrogen)
containing the rA2PIC peptide was prepared as described
previously [8].
Methods
DNA manipulations
Isolation of plasmid DNA was done as described by the
manufacturer. DNA fragments generated by restriction
endonuclease cleavage were purified on 1.2 or 0.5%
(depending on their size) agarose gels, stained with ethidium
bromide and visualized by UV light. DNA fragments were
recovered from the agarose gels by the E.Z.N.A.MicroSpin
Gel Extraction Kit according to the supplier’s instructions.
Construction of expression vectors for wild-type and
mutant rA2PIC peptides
The C-terminal region of A2PI (Asn398-Lys452) was
amplified in a PCR using the pET100/D-TOPO plasmid
containing rA2PIC or rA2PIC(Lys452Ala) as a template.
The 50 primer F/rA2PIC, which binds to the FXa cleavage
site of the sense strand of the pET100/D-TOPO plasmid
and the first four bases of rA2PIC, introduced a KpnI and a
FXa cleavage site upstream of the codon for Asn
398. The 30
primer R/rA2PIC, complementary to the coding strand of
rA2PIC, was used to introduce two stop codons and a
BamHI cleavage site downstream of the codon for Lys452.
Primers used are listed in Table 1. The KpnI and BamHI
cleaved PCR product was cloned into the KpnI-/BamHI-
digested pColdII plasmid and transformed into XL1-Blue
E. coli cells. Clones were selected and the insert was ver-
ified by DNA sequence analysis at Microsynth (Balgach,
Switzerland).
For the construction of the expression vectors rA2PIC
(Lys452Ala) and rA2PIC(Lys452Ser) the 30-mismatch
primers Lys452Ala and Lys452Ser (Table 1) were used,
respectively. The point mutation at the position Lys452
to Ser was introduced to improve the solubility of
rA2PIC(Lys452Ala).
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Construction of expression vectors for single, double,
triple, quadruple, quintuple, and sextuple Lys to Ala mutant
rA2PIC peptides by site-directed mutagenesis
The method used is based on the QuikChange Site-
Directed Mutagenesis Kit (Stratagene). In brief, the
appropriate pColdII expression vector (0.5 lg/lL) was
selected as template and used in a PCR with the suitable 50
primer in a concentration of 1.25 lg/lL. Primers used are
listed in Table 1. After amplification, the template DNA
was digested by adding 1 lL DpnI (8 h at 37C). 4% of
DpnI-digested PCR product was then transformed into
XL1-Blue E. coli cells. Clones were selected and the insert
was verified by DNA sequence analysis.
Substitution of Pro399 to Ala in all rA2PIC peptides
A point mutation at position Pro399 was introduced in all
rA2PIC peptides using site-directed mutagenesis as
described above, to improve the cleavage efficiency of FXa
[41, 42]. The Pro399Ala primer is shown in Table 1. All
mentioned rA2PIC peptides in this publication are here-
after referred to as carriers of the Pro399Ala mutation.
Construction of the pColdIImut(pelB) vector
To overcome the poor expression yields with the pColdII
expression system for certain constructs, we have modified
the pColdII vector by introducing the pelB leader sequence,
which can also be used as enhancer for the total protein
expression [43], between the TEE and His-tag sequence of
the pColdII vector. pColdIImut was amplified in a PCR
using the pColdII vector as template. The 50 primer
F/pColdIImut and 30 primer R/pColdIImut were used to
introduce a SpeI cleaving site (ACTAGT) between the TEE
and the His-tag sequences. Cleavage with SpeI and liga-
tion, followed by transformation into XL1-Blue E. coli
cells and selection of appropriate clones, yielded the
mutated pColdIImut vector. The pelB leader sequence was
amplified in a PCR using the pET22b(?) vector as a
template. The 50 primer F/pelB and 30 primer R/pelB were
used to introduce a SpeI cleaving site up- and downstream
of the pelB leader sequence. The SpeI cleaved PCR product
was cloned into the SpeI-digested pColdIImut plasmid and
transformed into XL1-Blue E. coli cells. Clones were
selected and the insert was verified by DNA sequence
analysis. The primers used are listed in Table 1.
Construction of the expression vector for rK5 and rK4–5
The rK5 construct (Thr456-Ala543) was amplified in a PCR
using the pPLGKG plasmid (contains the cDNA of human
Pgn) as a template. The 50-mismatch primer F/rK5, which
binds to the sense strand of Pgn, introduced a KpnI and a
FXa cleavage site upstream of the codon for Thr
456. This
50-mismatch primer was also used to introduce a point
mutation at position Pro457 to Ala to enhance the cleavage
efficiency of FXa [41, 42]. The 3
0 primer R/rK5, comple-
mentary to the coding strand of Pgn, was used to introduce
two stop codons and a BamHI cleavage site downstream of
the codon for Ala543. The primers used are compiled in
Table 1. The cloning, transformation, and verification of
Table 1 Primers used for the
generation of rA2PIC mutants,
pColdIImut vector, rK5, and
rK4–5
Mismatched bases are shown in
bold type
Primer name DNA sequence
F/pelB 50-GGCGACTAGTATGAAATACCTGCTGCCGACCG-30
R/pelB 50-CGGCACTAGTCGAATTAATTCCGATATCCATGGCC-30
F/pColdIImut 50-GGCGACTAGTCATCATCATCATCATCATATGGAGCTCGG-30
R/pColdIImut 50-CGGCACTAGTCACTTTGTGATTCATGGTGTATTACCTC-30
F/rA2PIC 50-CACCGGTACCATCGAGGGTAGAAACC-30
R/rA2PIC 50-GCGCGGATCCCTATTACTTGGG-30
F/rK4–5 50-CACCGGTACCATCGAGGGTAGAGTACAGGACTGCTACCAT-30
R/rK4–5 50-CGCGGGATCCCTATTAAAATGAAGGGGCCGCACA-30
F/rK5 50-CACCGGTACCATCGAGGGTAGAACTGCATCCGAAGAAGACTGTATG-30
R/rK5 50-CGCGGGATCCCTATTAGGCCGCACACTGAGGGACAT-30
Lys406Ala 50-GCGGGAGCTCGCGGAACAGCAGGATTC-30
Lys415Ala 50-GATTCCCCGGGCAACGCGGACTTCCTCCAGAG-30
Lys422Ala 50-TTCCTCCAGAGCCTGGCAGGCTTCCCCCG-30
Lys429Ala 50-GGCTTCCCCCGCGGAGACGCGCTTTTCGGCCCTGACTT-30
Lys436Ala 50-GCTTTTCGGCCCTGACTTAGCACTTGTGCCCCCCATGGAG-30
Lys452Ala 50-GCGCGGATCCCTATTAAGCGGG-30
Lys452Ser 50-CGCGGGATCCCTATTAAGAGGGGCTGCCAAACTGGGGG-30
Pro399Ala 50-CGAGGGTAGAAACGCCAGTGCACCGC-30
1508 S. S. Gerber et al.
clones was carried out according to the above-described
procedure for the construction of expression vectors for
wild-type and mutant rA2PIC peptides except that the
pColdIImut(pelB) vector was used. The mentioned rK5
in this article is hereafter referred to as rK5 construct
(Thr456-Ala543) and carrier of the Pro457Ala mutation.
The rK4–5 construct (Val355-Phe546) was generated as
described above except that 50 primer F/rK4–5, 30 primer
R/rK4–5 and pColdII were used. The mentioned rK4–5 in
this publication is hereafter referred to as rK4–5 construct
(Val355-Phe546).
Expression and isolation of wild-type and mutant rA2PIC
peptides
The expression was carried out according to a slightly
modified protocol of the manufacturer’s instructions. The
agar plates and LB Broth culture media always contained
100 lg ampicillin/mL and 34 lg chloramphenicol/mL.
Cells were grown at 37C in LB Broth medium in 2-L
Erlenmeyer flasks to an OD600 of about 0.4–0.6 absorbance
units (AU). The cell cultures were refrigerated at 15C for
35 min before isopropyl-b-D-thiogalactopyranoside was
added to a final concentration of 2 mM. The cultures were
thereafter incubated at 15C and 220rpm for 21–24 h and
finally harvested by centrifugation (Sorvall RC 3C Plus,
4,000g, 65 min, 4C). The cell pastes were stored at -80C
until further use. The protein expression was verified by
SDS-PAGE (15%) and the proteins were stained with
Coomassie brilliant blue G-250.
For the isolation of wild-type and mutant rA2PIC pep-
tides, the cell pastes were thawed and suspended in lysis
buffer (6 M guanidine hydrochloride and 300 mM NaCl in
50 mM Tris, pH 8.0; 10 mL/g of wet cell paste), stirred
overnight at 4C and centrifuged (Sorvall RC 5B Plus,
12,000g, 45 min, 4C). The supernatants were loaded onto a
Ni2?-NTA Agarose column (2.2 cm 9 9 cm; 1 mL Ni2?-
NTA Agarose/1,000 mL cell culture) equilibrated with the
lysis buffer, pH 8.0. The column was thereafter washed with
lysis buffer, pH 8.0 and 6.3. The recombinant peptides were
eluted from the columns with lysis buffer, pH 4.5. The
peptides were desalted by dialysis against 20 mM
NH4HCO3, lyophilized and stored at 4C until further use.
The peptides were analyzed by RP-HPLC, amino acid
analysis, ESI-MS, and Edman sequence analysis.
Expression, isolation, and characterization of recombinant
kringle constructs rK1, rK3, rK5, and rK4–5
rK1 and rK3 were expressed, isolated, refolded and char-
acterized according to Marti et al. [44, 45].
rK4–5 and rK5 were expressed and isolated according to
the above-described protocol for wild-type and mutant
rA2PIC peptides except that the proteins were refolded
instead of desalting by dialysis. rK4–5 was refolded and
isolated according to Douglas et al. [46]. rK5 was refolded
according to the same protocol as rK4–5 [46]. In addition,
isolated rK5 was lyophilized and further purified by size
exclusion chromatography on a Sephadex G-50sf column
(1.5 cm 9 100 cm; 0.13 M formic acid). The constructs
were analyzed as mentioned above.
Isolation of human plasminogen and generation
of the K1–3 and K4 domains
Pgn was isolated from citrated plasma by affinity chro-
matography on Lysine Bio-Gel P-300 as previously
described [38]. K1–3 and K4 were prepared via limited
proteolysis of Pgn with porcine elastase, isolated and
purified as previously described [25].
Purification and characterization of the synthetic peptides
A2PIC(Glu442-Lys452) with and without sulfated Tyr445
The synthetic peptides A2PIC(Glu442-Lys452) and A2PIC
(Glu442-Lys452/Tyr445[SO4]) were purified by preparative
RP-HPLC on a butyl column (Wide-PoreTM, 5 lm,
4.6 mm 9 250 mm; J.T. Baker) with a Hewlett-Packard
liquid chromatograph 1090. 50 mM ammonium acetate in
water, pH 7.0, was used as solution A and 25 mM
ammonium acetate, 80% (v/v) acetonitrile in water, pH 7.0,
as solution B. A linear gradient (0–60% solution B in
60 min) was used at a flow rate of 1 mL/min.
RP-HPLC
RP-HPLC separations were carried out on an Aquapore
butyl column (BU-300, 7 lm, 300 A˚, 2.1 mm 9 100 mm;
Perkin Elmer) or on a Nucleosil 300 phenyl column (7 lm,
2 mm 9 100 mm; Dr. Maisch HPLC, Ammerbuch,
Germany) with a Hewlett-Packard liquid chromatograph
1090. 0.1% (v/v) trifluoroacetic acid (TFA) in water was
used as solution A and 0.1% (v/v) TFA, 80% (v/v) aceto-
nitrile in water as solution B. A linear gradient (0–100%
solution B in 60 min) was used at a flow rate of 0.3 mL/min.
Amino acid analysis
Samples were hydrolyzed in the gas phase with 6 M HCl
containing 0.1% (v/v) phenol for 22 h at 115C under N2
vacuum according to Chang and Knecht [47]. The liberated
amino acids were reacted with phenylisothiocyanate, and
the resulting phenylthiocarbamoyl amino acids were ana-
lyzed by RP-HPLC on a Nova Pack C18 column (4 lm,
3.9 mm 9 150 mm; Waters) with a Dionex Summit
HPLC system (Dionex, Olten, Switzerland) equipped with
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an automatic injection system according to Bidlingmeyer
et al. [48]. The corresponding ammonium acetate buffer
replaced the 0.14 M sodium acetate buffer, pH 6.3.
Mass spectrometry
The mass of the peptides was determined by ESI-MS (VG
Platform mass spectrometer; Micromass Instruments, UK).
The samples were dissolved in 0.5% (v/v) formic acid,
50% (v/v) acetonitrile in water.
Removal of the His-tag sequence
To remove the His-Tag, constructs were incubated with
FXa at 37C for 16 h in 50 mM Tris, pH 8.0, containing
100 mM NaCl and 5 mM CaCl2 at an enzyme/substrate
ratio 1:800 (w/w). Cleaved peptides were separated from
His-tag and undigested constructs on a Ni2?-NTA Agarose
column (2.2 cm 9 9 cm). rA2PIC and rK5, both without
His-tag, were finally desalted either on a Sephadex G-50m
or on a Bio-Gel P-6DG column (1.5 cm 9 100 cm)
(50 mM NH4HCO3, pH 8.0).
Tryptic peptide mass mapping
For an explicit identification of the diverse rA2PIC
mutants, the peptides were digested with trypsin at 37C
overnight in 0.1 M NH4HCO3 at an enzyme/substrate ratio
1:100 (w/w). The peptide mass mapping was carried out by
ESI-MS.
Intrinsic fluorescence titration
The influence of wild-type and mutant rA2PIC peptides
on the intrinsic fluorescence of different Pgn kringles
was measured in 50 mM sodium phosphate, pH 8.0, at
25C with a Cary Eclipse fluorescence spectrophotometer
(Varian) as reported by Menhart et al. [49]. The ligand
(wild-type and mutant rA2PIC) was added to a 5-lM
kringle solution at intervals of 1.66, 3.3, 5, 10, 20, 33, or
40 lM depending on the binding affinity of the investi-
gated kringle until the intrinsic fluorescence was
constant. Fluorescence was measured at 340 or 344 nm,
depending on the investigated kringle, with excitation
at 296 nm. Ka values were determined according to
Scatchard [50].
A threefold determination of the peptide content in the
ligand solutions by amino acid analysis allowed an accu-
rate evaluation of the Ka values.
The Ka values for the interaction of A2PIC
(Glu442-Lys452) and A2PIC(Glu442-Lys452/Tyr445[SO4])
with Pgn rK3 and K4 were obtained as described above.
Results
Recombinant expression of rA2PIC and rA2PIC
mutants
We have successfully applied the pColdII expression sys-
tem to improve the expression of rA2PIC and rA2PIC
mutants. The identification of rA2PIC peptides by SDS-
PAGE showed a main band indicating a relatively high
level of expression (data not shown). The expression yield
of the rA2PIC mutants was in the range of 5–35 mg of pure
peptide/2 L of cell culture due to variable expression levels
of the rA2PIC constructs. The introduction of the point
mutation at position Pro399 to Ala dramatically enhanced
the cleavage efficiency of FXa, since it has been shown that
the P20 position at the FXa cleavage site (IEGR) is
important for the enzymatic activity of FXa [41, 42]. We
could overcome the poor solubility of rA2PIC(Lys452Ala)
by introducing a Lys452 to Ser mutation. All rA2PIC pep-
tides eluted as sharp, symmetrical peaks on RP-HPLC
columns. After removal of the His-tag, the measured
masses agree well with the calculated values (Table 2).
Amino acid analyses and Edman sequence analyses yielded
the expected compositions and N-terminal sequences (data
not shown), respectively, and both methods were applied
for the characterization of all following constructs.
Recombinant expression, purification, and refolding
of Pgn rK1, rK3, rK5, and rK4–5
rK1 and rK3 were expressed in E. coli, purified, refolded,
and characterized as previously described [44, 45]. The
isolation over Lysine Bio-Gel P-300 ensured that the
Table 2 Characterization of rA2PIC peptides by ESI-MS (experi-
mental and theoretical values)
Construct Mass (exp.)
(Da)
Mass (theor.)
(Da)
rA2PIC(wt) 6,145.0 ± 0.4 6,145.9
rA2PIC/K406A 6,087.4 ± 0.5 6,088.8
rA2PIC/K415A 6,087.5 ± 0.8 6,088.8
rA2PIC/K422A 6,087.9 ± 0.6 6,088.8
rA2PIC/K429A 6,088.0 ± 0.6 6,088.8
rA2PIC/K436A 6,088.8 ± 1.2 6,088.8
rA2PIC/K452A 6,088.0 ± 0.1 6,088.8
rA2PIC/K452S 6,104.3 ± 0.2 6,104.8
rA2PIC/K436/452A 6,031.1 ± 0.3 6,031.7
rA2PIC/K429/452A 6,031.4 ± 0.2 6,031.7
rA2PIC/K429/436A 6,031.8 ± 0.2 6,031.7
rA2PIC/K422/429/436A 5,974.3 ± 0.4 5,974.6
rA2PIC/K415/422/429/436A 5,917.3 ± 0.7 5,917.5
rA2PIC/K406/415/422/429/436A 5,860.4 ± 0.4 5,860.4
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disulfide bridges were folded correctly. The measured
masses of 10,167.3 ± 0.6 Da for rK1 and 9,503.8 ±
1.0 Da for rK3 correspond well with the calculated masses
of 10,167.2 and 9,505.4 Da, respectively.
rK5 was successfully expressed in E. coli using the
pColdIImut(pelB) vector with which we achieved a
significantly higher expression yield compared to the
unmodified pColdII plasmid. A point mutation at position
Pro457 to Ala was introduced to enhance the cleavage
efficiency of FXa as mentioned above. The identification of
rK5 by SDS-PAGE showed a main band indicating a
relatively high level of expression (data not shown). The
expression yield was about 19 mg of pure protein/2 L of
cell culture. rK5 was isolated as described above and
refolded according to Marti et al. [44, 45]. The measured
mass of 9,769.0 ± 0.6 Da corresponds well with the cal-
culated value of 9,768.7 Da.
rK4–5 was successfully cloned into the pColdII vector
and expressed in E. coli [51]. Approximately 5–10 mg of
pure protein/2 L of cell culture was obtained. rK4–5 was
isolated and refolded as described for rK5 and the mea-
sured mass of 23,734.1 ± 4.9 Da corresponds well with
the calculated mass of 23,735.3 Da.
Characterization of the purified synthetic peptides
A2PIC(Glu442-Lys452/Tyr445[SO4])
and A2PIC(Glu442-Lys452)
The measured masses of 1,295.8 ± 0.3 Da for A2PIC
(Glu442-Lys452) and 1,376.1 ± 0.3 Da for A2PIC(Glu442-
Lys452/Tyr445[SO4]) correspond well with the calculated
masses of 1,296.4 and 1,376.4 Da, respectively.
Binding of wild-type and mutant rA2PIC
to human Pgn K4
Wild-type rA2PIC exhibits a Ka value of 34 ± 2 mM
-1 for
Pgn K4, which is in the range of previously published data
[18]. Replacing the C-terminal Lys452 residue by either Ser
or Ala substantially decreases the affinity (rA2PIC(K452S),
Ka = 11 ± 2 mM
-1) by a factor of *3. Our data confirm
that Lys452 is the main binding partner in the interaction with
the isolated K4 domain in solution, which is in good
agreement with published data [18]. The single Lys to Ala
mutants of the totally conserved internal Lys residues Lys436
(Ka = 32 ± 2 mM
-1), Lys429 (Ka = 33 ± 2 mM
-1), and
Lys422 (Ka = 33 ± 3 mM
-1), and the partially conserved
Lys415 (Ka = 44 ± 6 mM
-1) and Lys406 (Ka = 42 ±
6 mM-1) contribute only to a minor extent to the total
binding affinity to the LBS of K4. The double rA2PIC(Lys
429Ala/Lys436Ala) (Ka = 29 ± 0.5 mM
-1), triple rA2PIC
(Lys422Ala/Lys429Ala/Lys436Ala) (Ka = 28 ± 1 mM
-1),
quadruple rA2PIC(Lys415Ala/Lys422Ala/Lys429Ala/
Lys436Ala) (Ka = 24 ± 1 mM
-1), and quintuple mutants
rA2PIC(Lys406Ala/Lys415Ala/Lys422Ala/Lys429Ala/
Lys436Ala) (Ka = 23 ± 2 mM
-1) exhibit a steady dec-
rease of the Ka values with a decreasing number of Lys
residues. The data confirm the weak affinity for internal
Lys residues to the LBS of K4 [18, 52, 53]. The sextuple
rA2PIC(Lys406Ala/Lys415Ala/Lys422Ala/Lys429Ala/
Lys436Ala/Lys452Ala) mutant exhibits a very weak affi-
nity (Ka = *3 mM
-1). A comparison of the fluorescence
titration and Scatchard plot of wild-type rA2PIC with
mutants rA2PIC(Lys436A), rA2PIC(Lys452Ser), and rA2PIC
(Lys406Ala/Lys415Ala/Lys422Ala/Lys429Ala/Lys436Ala)
is given in Fig. 1 and all Ka values are summarized in
Table 3. The determined Ka value for 6-AHA of 46 ±
4 mM-1 was in good agreement with published data [18].
Binding of wild-type and mutant rA2PIC to Pgn rK1
The wild-type rA2PIC exhibits a Ka value of 77 ± 4 mM
-1
for Pgn rK1 and replacement of the C-terminal Lys452
Fig. 1 a Averaged fluorescence titration of K4 with wild-type
rA2PIC (filled squares), single Lys to Ala mutants rA2PIC
(Lys436Ala) (filled triangles), and rA2PIC(Lys452Ser) (star), and
quintuple mutant rA2PIC(Lys406Ala/Lys415Ala/Lys422Ala/Lys429Ala/
Lys436Ala) (filled circles). The fluorescence intensity is normalized
to 1 and the x-axis is enlarged. b Corresponding Scatchard plots and
calculated regression curves
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residue by Ser or Ala decreases the affinity (rA2PIC
(Lys452Ser), Ka = 8 ± 0.5 mM
-1) by a factor of *10,
which is in good agreement with published data [18]. The
double mutant rA2PIC(Lys429Ala/Lys452Ala) (Ka = 8 ±
0.5 mM-1) exhibits the same Ka value as the single mutant
rA2PIC(Lys452Ser), while the single mutant of internal
Lys436 rA2PIC(Lys436Ala) (Ka = 70 ± 1 mM
-1) shows
no significant difference compared to the wild-type
rA2PIC. The quintuple mutant rA2PIC(Lys406Ala/
Lys415Ala/Lys422Ala/Lys429Ala/Lys436Ala) (Ka = 53 ±
7 mM-1) exhibits a partially decreased affinity compared
to the wild-type rA2PIC. The sextuple mutant rA2PIC
(Lys406Ala/Lys415Ala/Lys422Ala/Lys429Ala/Lys436Ala/
Lys452Ala) shows a weak Ka value of*3 mM
-1. Our data
confirm that Lys452 is the main binding partner in the
interaction with the isolated rK1 domain in solution, which
is in good agreement with published data [18], and that rK1
exhibits only a weak but distinct affinity for internal Lys
residues [18, 52, 53]. A selection of the fluorescence
titrations and Scatchard plots of wild-type rA2PIC, single
rA2PIC(Lys436A) and rA2PIC(Lys452Ser), double rA2PIC
(Lys429Ala/Lys452Ala), and quintuple rA2PIC(Lys406Ala/
Lys415Ala/Lys422Ala/Lys429Ala/Lys436Ala) mutants is
shown in Fig. 2 and all Ka values are summarized in
Table 3. The Ka value of 75 ± 11 mM
-1 for 6-AHA was
determined by Frank et al. [18] and is in the same range as
wild-type rA2PIC.
Binding of wild-type and mutant rA2PIC
to human Pgn K1–3
The Ka values of wild-type rA2PIC (Ka = 176 ±
30 mM-1) and internal single mutants of the totally con-
served Lys429 (Ka = 170 ± 9 mM
-1) and Lys422 (Ka =
177 ± 22 mM-1) for Pgn K1–3 are in a similar range.
The Ka values drop dramatically after replacement of
the C-terminal Lys452 (rA2PIC(Lys452Ser), Ka = 17 ±
4 mM-1) or the internal Lys436 (rA2PIC(Lys436Ala),
Ka = 26 ± 10 mM
-1) residue by Ser or Ala, respectively.
The double rA2PIC(Lys429Ala/Lys436Ala) (Ka = 17 ±
6 mM-1) and rA2PIC(Lys429Ala/Lys452Ala) (Ka = 30 ±
5 mM-1), triple rA2PIC(Lys422Ala/Lys429Ala/Lys436Ala)
(Ka = 22 ± 7 mM
-1), quadruple rA2PIC(Lys415Ala/
Lys422Ala/Lys429Ala/Lys436Ala) (Ka = 12 ± 2 mM
-1),
and quintuple rA2PIC(Lys406Ala/Lys415Ala/Lys422Ala/
Lys429Ala/Lys436Ala) (Ka = 46 ± 12 mM
-1) mutants
exhibit a highly reduced affinity, thus confirming the
importance of the Lys452 and Lys436 residues in the inter-
action with the isolated triple-kringle domain K1–3 in
solution. The fluorescence titrations and Scatchard plots
of wild-type rA2PIC, single rA2PIC(Lys436A) and
rA2PIC(Lys452Ser), double rA2PIC(Lys429Ala/Lys452Ala),
and quintuple rA2PIC(Lys406Ala/Lys415Ala/Lys422Ala/
Lys429Ala/Lys436Ala) mutants are shown in Fig. 3. The
sextuple mutant rA2PIC(Lys406Ala/Lys415Ala/Lys422Ala/
Lys429Ala/Lys436Ala/Lys452Ala) exhibits a very weak
affinity (Ka = *4 mM
-1) and the Lys analog 6-AHA
exhibits a Ka value of 107 ± 11 mM
-1, which is consid-
erably smaller compared to that of wild-type rA2PIC. All
Ka values are summarized in Table 3.
Binding of wild-type and mutant rA2PIC
to Pgn rK4–5 and rK5
The Ka value of wild-type rA2PIC (Ka = 18 ± 1 mM
-1)
for the rK4–5 double-kringle domain is smaller than for K4
alone. As in K4 and rK1, the C-terminal Lys452 (rA2PIC
(Lys452Ser), Ka = 1.4 ± 0.5 mM
-1) is the main binding
partner for the interaction with the LBS of isolated rK4–5
in solution. The single rA2PIC(Lys436Ala) (Ka = 16 ±
2 mM-1), double rA2PIC(Lys429Ala/Lys436Ala) (Ka =
16 ± 5 mM-1), triple rA2PIC(Lys422Ala/Lys429Ala/
Lys436Ala) (Ka = 18 ± 5 mM
-1), quadruple rA2PIC
(Lys415Ala/Lys422Ala/Lys429Ala/Lys436Ala) (Ka = *17
mM-1), and quintuple rA2PIC(Lys406Ala/Lys415Ala/
Lys422Ala/Lys429Ala/Lys436Ala) (Ka = 17 ± 4 mM
-1)
mutants exhibit comparable affinities to the LBS of rK4–5
as wild-type rA2PIC. The sextuple mutant rA2PIC
(Lys406Ala/Lys415Ala/Lys422Ala/Lys429Ala/Lys436Ala/
Lys452Ala) shows no detectable change in intrinsic fluo-
rescence and an accurate Ka value could not be determined.
6-AHA exhibits a Ka value of *52 mM
-1, which is sig-
nificantly higher than the Ka value of wild-type rA2PIC.
All Ka values are summarized in Table 3.
Due to the low affinity of K5 for Lys residues, no sig-
nificant fluorescence change could be detected. This is
consistent with earlier studies, which showed the very
weak affinity of K5 for C-terminal and internal Lys resi-
dues [18, 54].
Binding of A2PIC(Glu442-Lys452/Tyr445[SO4])
and A2PIC(Glu442-Lys452) to Pgn rK3 and K4
rK3 was used for intrinsic fluorescence titrations with the
short synthetic C-terminal segments A2PIC(Glu442-Lys452)
and A2PIC(Glu442-Lys452/Tyr445[SO4]) to investigate the
influence of the sulfated Tyr445 residue. The A2PIC
(Glu442-Lys452/Tyr445[SO4]) exhibits a very weak affinity
with a Ka value of *3 ± 1 mM
-1 and is in a comparable
range to the non-sulfated peptide A2PIC(Glu442-Lys452)
(Ka = *5 ± 1 mM
-1).
K4 was used to confirm the ability of A2PIC
(Glu442-Lys452) and A2PIC(Glu442-Lys452/Tyr445[SO4]) to
bind to the LBS of Pgn kringles. The Ka values of
A2PIC(Glu442-Lys452/Tyr445[SO4]) (Ka = 29 ± 4 mM
-1)
and A2PIC(Glu442-Lys452) (Ka = 24 ± 4 mM
-1) are in a
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similar range (see Table 3). The quintuple mutant rA2PIC
(Lys406Ala/Lys415Ala/Lys422Ala/Lys429Ala/Lys436Ala)
(Ka = 23 ± 2 mM
-1) and the synthetic C-terminal peptide
A2PIC(Glu442-Lys452) (Ka = 24 ± 4 mM
-1), both con-
taining only the C-terminal Lys452, show very similar
binding affinities.
Discussion
Our investigations of wild-type and single, double, triple,
quadruple, quintuple, and sextuple Lys to Ala mutants of
the Pgn-binding region of A2PI (Asn398-Lys452), rA2PIC,
via intrinsic fluorescence titrations, identify the C-terminal
Lys452 as the main binding partner in the interaction with
the LBS of isolated K4 in solution, which is consistent with
published data [8, 18]. We could show that all internal Lys
residues (Lys436, Lys429, Lys422, Lys415 and Lys406) con-
tribute only to a minor but distinct extent to the binding to
the LBS of K4, which is demonstrated by a steady decrease
of the Ka values with a decreasing number of Lys residues.
We find similar results for isolated rK1, which is also
consistent with published data [8, 18], and the double-
kringle domain rK4–5 and the triple-kringle domain K1–3
in solution. The Ka value for wild-type rA2PIC and rK4–5
is smaller than for wild-type rA2PIC and K4, which could
be due to a shielding effect of the rK5 domain in the flex-
ible rK4–5 double-kringle domain or due to the N-terminal
His-tag, which was still present. Due to the weak binding
affinity of K5 to internal and C-terminal Lys residues
[18, 54], we could not detect a significant change in the
intrinsic fluorescence of isolated rK5 in solution. Frank
et al. [18] found that the Ka values for wild-type rA2PIC
with isolated rK2, rK3mut (contains an active LBS in
contrast to wild-type rK3, which is devoid of a functionally
active LBS [45]) and K5 in solution are in the range of
3–4 mM-1, which is indicative for a minor importance of
these Pgn kringles in the interaction with wild-type
rA2PIC. In contrast to these findings with isolated kringle
domains, we identified Lys452 and Lys436 as important
binding partners for the interaction with the isolated triple-
kringle domain K1–3 in solution. The association constant
of K1–3 for wild-type rA2PIC is two- to threefold
increased compared to rK1, and replacing of the conserved
internal Lys422 and Lys429 with Ala does not affect this
enhanced binding affinity for K1–3. In addition, we could
also demonstrate that the other internal Lys residues
(Lys415 and Lys406) do not contribute significantly in the
binding to the LBS of K1–3 and that the quintuple mutant
rA2PIC(Lys406Ala/Lys415Ala/Lys422Ala/Lys429Ala/
Lys436Ala) exhibits a Ka value which is in the same range
(Ka = *50 mM
-1) as for the interaction with isolated
rK1. This enhanced binding affinity of K1–3 for wild-type
rA2PIC points towards a cooperative effect of Lys452 and
Lys436, since it has been shown that the binding affinity of
isolated rK2 in solution for Lys residues is very low [18,
44]. Our data underscore the fact that the Lys residues in
the unique A2PIC mediate the binding to Pgn kringle
domains [19–21, 31–34]. Wang et al. [36, 37] found in
their kinetic studies with A2PI mutants that Lys436 is
important for the interaction with plasmin in solution,
immobilized plasminogen, or immobilized K1–3. They
showed, in contrast to our findings, that Lys452 is not
involved in this non-covalent interaction. The question
Table 3 Association constants
Ka (mM
-1) of wild-type and
mutant rA2PIC peptides
to various kringle constructs
of Pgn
a From [18]
Ligand rK1 K1–3 K4 rK4–5
6-AHA 75 ± 11a 107 ± 11 46 ± 4 *52
Wild type 77 ± 4 176 ± 30 34 ± 2 18 ± 1
K406A 42 ± 6
K415A 44 ± 6
K422A 177 ± 22 33 ± 3
K429A 170 ± 9 33 ± 3
K436A 70 ± 1 26 ± 10 32 ± 2 16 ± 2
K452S 8 ± 0.5 17 ± 4 11 ± 2 1.4 ± 0.5
K452A 11.6 ± 0.5a 9.1 ± 0.2a
K429/36A 17 ± 6 29 ± 0.5 16 ± 5
K429/52A 8 ± 0.5 30 ± 5
K422/29/36A 22 ± 7 28 ± 1 18 ± 5
K415/22/29/36A 12 ± 2 24 ± 1 *17
K406/15/22/29/36A 53 ± 7 46 ± 12 23 ± 2 17 ± 4
K406/15/22/29/36/52A *3 *4 *3
A2PIC(E442-K452/Y445[SO4]) 29 ± 4
A2PIC(E442-K452) 24 ± 4
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arises, why the C-terminal Lys452 should be of no impor-
tance since it has been shown that the LBS of rK1 and K4
exhibit a much higher affinity for Na-acetyllysine, a ligand
that mimics C-terminal lysines, than for Na-acetyllysine
methyl ester, a mimic of internal Lys residues [18, 44, 52,
53]. Furthermore, another interesting fact supports the
importance of Lys452. As Frank et al. [18] have already
discussed, the distance between the last two lysines (Lys436
and Lys452) in fully extended linear A2PIC is *30 A˚,
which would match the distance required to bridge the
LBSs of K1 and K2 as estimated from the K1–3 crystal
structure [55], where the distance from Trp144 (K1 LBS) to
Trp225 (K2 LBS) is *30 A˚. This bridging seems to point
towards an induced-fit model, where the binding of Lys452
to the LBS of K1 is reinforced by the binding of Lys436 to
the LBS of K2, which results in a conformational change
of the K1–3 triple-kringle construct as a whole, rather
than structural changes within domains, resulting in an
enhanced binding compared to isolated rK1 or rK2 in
solution. This hypothesis is supported by the fact that the
multi-kringle domains are very flexible structures, since the
conformational change upon activation of Pgn to Plm is
quite dramatic (reviewed in [27]). Another fact derived
from the X-ray crystal structure, supporting the importance
of the Lys452 and Lys436 residues, is that the C-terminal
extension lies close to the RCL in such a way that the more
distal conserved Lys residues (Lys452 and Lys436) could
readily engage the kringles in binding [22]. In addition,
Sofian et al. [56] prepared three peptides, peptide 1
(Asn398-Leu421), peptide 2(Asp416-Leu435), and peptide
3(Leu430-Lys452), and the corresponding antibodies to these
different regions of A2PIC, and investigated their effects
on plasmin–antiplasmin kinetics and fibrinolysis. They
could show that peptide 3 and antibody 3 exhibit a*10-fold
decrease of the rate of association between A2PI and Plm,
which underscores the importance of Lys452 and Lys436,
whereas peptides 1 and 2 and antibodies 1 and 2,
corresponding to the remaining internal Lys residues
Fig. 2 a Averaged fluorescence titration of rK1 with wild-type
rA2PIC (filled squares), single Lys to Ala mutants rA2PIC
(Lys436Ala) (filled triangles), and rA2PIC(Lys452Ser) (star), double
rA2PIC(Lys429Ala/Lys452Ala) (filled diamonds), and quintuple
rA2PIC(Lys406Ala/Lys415Ala/Lys422Ala/Lys429Ala/Lys436Ala)
(filled circles) mutants. The fluorescence intensity is normalized to 1
and the x-axis is enlarged. b Corresponding Scatchard plots and
calculated regression curves
Fig. 3 a Averaged fluorescence titration of K1–3 with wild-type
rA2PIC (filled squares), single Lys to Ala mutants rA2PIC
(Lys436Ala) (filled triangles) and rA2PIC(Lys452Ser) (star), double
rA2PIC(Lys429Ala/Lys452Ala) (filled diamonds), and quintuple
rA2PIC(Lys406Ala/Lys415Ala/Lys422Ala/Lys429Ala/Lys436Ala)
(filled circles) mutants. The fluorescence intensity is normalized to 1
and the x-axis is enlarged. b Corresponding Scatchard plots and
calculated regression curves
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(Lys429/Lys422 and Lys415/Lys406, respectively), seemed to
have no significant effect on the serpin inhibition reaction.
Nevertheless, it might be possible that the C-terminal
segment adopts different conformations in the whole A2PI
or as peptide in solution. These conformational differences
could result in different binding affinities for kringle
domains. However, the structure of the unique A2PIC
remains unsolved [22], leaving the question of different
conformations open. In addition, we have expressed
recombinant A2PI and Lys to Ala mutants in the C-ter-
minal segment of A2PI at high levels in E. coli [51]. No
binding affinities could be determined due to extremely
low solubility of the recombinant A2PI constructs at
physiological conditions (pH and salts). Furthermore,
Frank et al. [18] demonstrated by NMR and CD mea-
surements that rA2PIC is a rather flexible polypeptide of
low b-structure supporting the discussed induced-fit model.
We also investigated the effect of sulfated Tyr445, which
is present in the unique C-terminal extension of native
human A2PI [15]. A possible function of this posttransla-
tional modification could be an interaction with Pgn K3,
which contains no active LBS [45] but a heparin-binding
site (Prof. Dr. M. Llina´s, personal communication). It is
therefore possible that sulfated Thyr445 in A2PIC might
interact with the heparin-binding site in K3. We applied
intrinsic fluorescence titrations to investigate the effect of
two synthetic peptides A2PIC(Glu442-Lys452) and A2PIC
(Glu442-Lys452/Tyr445[SO4]) on the interaction with iso-
lated Pgn rK3 in solution. The Ka values of *3 ± 1 mM
-1
for the sulfated and *5 ± 1 mM-1 for the non-sulfated
A2PIC(Glu442-Lys452) revealed that sulfated Tyr445 has no
detectable effect on the interaction of rK3 and A2PIC
(Glu442-Lys452/Tyr445[SO4]) in solution. To ensure that the
two synthetic peptides are capable of binding to the LBS in
kringle domains, we investigated the binding of A2PIC
(Glu442-Lys452) and A2PIC(Glu442-Lys452/Tyr445[SO4]) to
isolated Pgn K4 in solution. The achieved Ka values of
29 ± 4 mM-1 for the sulfated and 24 ± 4 mM-1 for the
non-sulfated A2PIC(Glu442-Lys452) are both in a similar
range. An interesting finding is that the Ka value of
A2PIC(Glu442-Lys452) is in the same range as the quintuple
mutant rA2PIC(Lys406Ala/Lys415Ala/Lys422Ala/Lys429
Ala/Lys436Ala), which also contains only the C-terminal
Lys452.
We further attempted to model the 3D structure of the
whole Pgn. The model is based on the amino acid sequence
of Pgn, which was used as a template for the automated
structure modeling using SWISS-MODEL [57–59]. Con-
nected and overlapping 3D structures of Pgn fragments
(K1–K2; Leu81-Thr245, parts of K3–K4; Thr291-Ser441,
parts of K4–K5; Leu402-Ala543, K1–K2–K3; Leu81-Cys333,
and K5; Asp461-Pro544) were selected and thereafter
assembled and attached to the 3D structure of the catalytic
domain of Plm (1BML) using the visualization and
rendering software PyMOL. The obtained model of the
whole plasmin(ogen) molecule is shown in Fig. 4. The 3D
structure model exhibits a spiral-type shape, which
resembles the known shape of Glu1-Pgn visualized by
Fig. 4 Model structure of the whole Pgn molecule. The model is
based on the amino acid sequence of Pgn, which was used as a
template for the automated structure modeling using SWISS-MODEL
[57–59]. Connected and overlapping 3D structures of Pgn fragments
(K1–K2; Leu81-Thr245, parts of K3–K4; Thr291-Ser441, parts of K4–
K5; Leu402-Ala543, K1–K2–K3; Leu81-Cys333, and K5; Asp461-Pro544)
were selected and thereafter assembled and attached to the 3D
structure of the catalytic domain of Plm (1BML) using the visual-
ization and rendering software PyMOL. Each kringle domain (K) is
shown in gray, the central Trp of each LBS is presented in pink, the
protease domain is colored in green, and the active site residues are
marked in red
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electron microscopy [60, 61]. An interesting finding is that
the LBS of K1, K4, and K5 are orientated opposite the
active site of the protease domain whereas the LBS of K2
and K3 are orientated towards it. The opposite orientation
of the LBS of K1 and K4 would allow Plm to bind to the
target surface and leave the active site in the protease
domain freely accessible. The model supports the findings
that the K1- and K4-LBS act as independent and comple-
mentary domains both able to support Pgn binding and
activation, and both seem to be required to ensure Pgn
anchorage and subsequent proteolytic activity [62]. The
remaining kringles seem to be involved in the modulation
of Plm activity rather than anchorage of Pgn to the target
surface since it has been shown that K5 interacts with long-
chain fatty acids [63] as well as various cell surface pro-
teins [64–66] and that K3 exhibits a heparin-binding site
(Prof. Dr. M. Llina´s, personal communication). The model
is also consistent with our findings, that isolated rK1 and
K4 exhibit a strong affinity for C-terminal Lys452, which
supports the independence of both domains [62], and that
the reinforced interaction between C-terminal Lys452 and
internal Lys436 in the interaction with the isolated K1–3
domain (two- to threefold increase compared to rK1)
underscores the high flexibility of multi-kringle domains
(reviewed in [27]) allowing Lys436 to interact with the LBS
of K2.
Conclusions
We could identify the C-terminal Lys452 as the main
binding partner in the interaction of rA2PIC with isolated
rK1, K4, and rK4–5 in solution. We could show a coop-
erative, zipper-like enhancement of the interaction between
Lys452 and internal Lys436 of the rA2PIC and the isolated
K1–3 triple-kringle domain in solution. The data allow the
assumption that the C-terminal Lys452 is the primary
binding partner whereas Lys436 functions as enhancer
rather than as the primary binding partner. A co-crystalli-
zation of rA2PIC and Pgn or the K1–5 multi-kringle
domain would definitively solve the interaction mechanism
between the kringle domains and A2PIC. Our findings
point towards a major interaction of the C-terminal Lys452
of rA2PIC with both LBS in K1 and K4, which act as
independent and complementary domains both required to
ensure Pgn anchorage and subsequent proteolytic activity,
and that the remaining kringles (K2, K3, and K5) seem to
be involved in the modulation of Plm activity rather than
anchorage of Pgn to the target surface. The function of
sulfated Tyr445 still remains to be solved.
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